| pubmed-article:1535229 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1535229 | lifeskim:mentions | umls-concept:C0019163 | lld:lifeskim |
| pubmed-article:1535229 | lifeskim:mentions | umls-concept:C0031228 | lld:lifeskim |
| pubmed-article:1535229 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
| pubmed-article:1535229 | lifeskim:mentions | umls-concept:C0231204 | lld:lifeskim |
| pubmed-article:1535229 | lifeskim:mentions | umls-concept:C1517942 | lld:lifeskim |
| pubmed-article:1535229 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1535229 | pubmed:dateCreated | 1992-7-30 | lld:pubmed |
| pubmed-article:1535229 | pubmed:abstractText | Two hundred and sixty-seven susceptible hospital personnel who had been randomly divided into three groups to receive different doses (5 micrograms, 2 micrograms or 1 microgram) of a plasma-derived hepatitis B vaccine on a four-dose schedule were investigated annually for 4 years. Of them, 251 were vaccine responders. The percentages of persistence of antibody to hepatitis B surface antigen (anti-HBs) in these 3 groups were 95.5% (84/88), 92.3% (72/78) and 95.3% (81/85), respectively (P greater than 0.05). During the follow-up period, 12 of 21 (57.1%) responders with low anti-HBs titres (10-100 miu/mL) and 3 of 48 (6.3%) responders with medium anti-HBs titres (101-1000 miu/mL) were found to be anti-HBs seronegative, while none of the 182 candidates with high anti-HBs levels (greater than 1000 miu/mL) lost their anti-HBs. The 4 year cumulative rate of natural booster in the responders was 11.6% (29/251). None of the candidates became HBsAg positive during the follow-up period. This study revealed that low dose hepatitis B vaccine can provide satisfactory immunogenic response and long-term efficacy in Chinese adults and that the persistence of immunogenicity is not related to the vaccine dose but to the candidate's own initial anti-HBs response. | lld:pubmed |
| pubmed-article:1535229 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1535229 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1535229 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1535229 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1535229 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1535229 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1535229 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1535229 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1535229 | pubmed:issn | 0815-9319 | lld:pubmed |
| pubmed-article:1535229 | pubmed:author | pubmed-author:HSUF KFK | lld:pubmed |
| pubmed-article:1535229 | pubmed:author | pubmed-author:ChanC YCY | lld:pubmed |
| pubmed-article:1535229 | pubmed:author | pubmed-author:LoK JKJ | lld:pubmed |
| pubmed-article:1535229 | pubmed:author | pubmed-author:SAROAA | lld:pubmed |
| pubmed-article:1535229 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1535229 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:1535229 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1535229 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1535229 | pubmed:pagination | 266-9 | lld:pubmed |
| pubmed-article:1535229 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:meshHeading | pubmed-meshheading:1535229-... | lld:pubmed |
| pubmed-article:1535229 | pubmed:articleTitle | Long-term follow-up of hepatitis B vaccination in susceptible hospital personnel. | lld:pubmed |
| pubmed-article:1535229 | pubmed:affiliation | Department of Medicine, Veterans General Hospital, Taipei, Taiwan, ROC. | lld:pubmed |
| pubmed-article:1535229 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1535229 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1535229 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:1535229 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
